Genetics, autoantibodies and clinical features in understanding and
predicting rheumatoid arthritis
Helm-van Mil, A.H.M. van der
Citation
Helm-van Mil, A. H. M. van der. (2006, October 26). Genetics, autoantibodies and clinical
features in understanding and predicting rheumatoid arthritis. Retrieved from
https://hdl.handle.net/1887/4929
Version:
Corrected Publisher’s Version
License:
Licence agreement concerning inclusion of doctoral thesis in the
Institutional Repository of the University of Leiden
Downloaded from:
https://hdl.handle.net/1887/4929
'ENETIC¬CONTRIBUTION¬TO¬2!¬SEVERITY
#HA
P
TER¬
'ENETIC¬CONTRIBUTION¬TO¬2!¬SEVERITY
2!¬PATIENTS¬TO¬DIZYGOTIC¬AND¬MONOZYGOTIC¬TWIN¬DATA¬AND¬OBSERVED¬AN¬INCREASE¬IN¬VARIATION IN¬ JOINT¬ DESTRUCTION¬ PARALLEL¬ TO¬ A¬ DECREASE¬ IN¬ GENETIC¬ SIMILARITY ¬ INDICATING¬ THAT¬ GENETICS FACTORS¬ARE¬IMPORTANT¬FOR¬THE¬SEVERITY¬OF¬JOINT¬DESTRUCTION¬IN¬2!
)T¬ MIGHT¬ BE¬ A¬ CONCERN¬ THAT¬ TWINS¬ AND¬ UNRELATED¬ 2!¬ PATIENTS ¬ ALTHOUGH¬ BOTH¬ #AUCA SIAN ¬CAME¬FROM¬DIFFERENT¬CONTINENTS¬(OWEVER ¬COMPARISON¬OF¬3HARP¬SCORES¬OF¬!MERICAN AND¬ $UTCH¬ EARLY¬ 2!¬ PATIENTS¬ NOT¬ TREATED¬ WITH¬ DISEASE MODIFYING¬ ANTIRHEUMATIC¬ DRUGS¬ $-!2$S ¬REVEALED¬SIMILAR¬SCORES¬ 4HE¬MOST¬IMPORTANT¬RISK¬FACTOR¬FOR¬2!¬SEVERITY¬IS¬THE¬AUTOANTIBODY¬STATUS¬4HE¬UNRELATED 2!¬PATIENTS¬WERE¬MATCHED¬FOR¬RHEUMATOID¬FACTOR¬COMPARABLE¬TO¬THE¬MONOZYGOTIC¬TWINS -ATCHING¬ON¬ANTI ##0¬STATUS¬WAS¬NOT¬POSSIBLE¬AS¬ANTI ##0¬ANTIBODIES¬WERE¬DETERMINED¬IN¬ ONLY¬A¬PART¬OF¬THE¬TWINS¬!S¬THE¬PRESENCE¬OF¬AUTOANTIBODIES¬ASSOCIATES¬WITH¬THE¬PRESENCE¬ OF¬(,! SHARED¬EPITOPE¬ALLELES¬ ¬IT¬IS¬LIKELY¬THAT¬BY¬MATCHING¬FOR¬AUTOANTIBODIES¬PATIENTS WERE¬ALSO¬PARTLY¬CORRECTED¬FOR¬DIFFERENCES¬IN¬SHARED¬EPITOPE¬STATUS¬4HIS¬MIGHT¬HAVE¬UNDER ESTIMATED¬THE¬DIFFERENCE¬IN¬VARIATION¬DUE¬TO¬GENETIC¬FACTORS 'IVEN¬THE¬HYPOTHETICAL¬EFFECT¬OF¬THE¬DIFFERENCE¬IN¬AGE¬OF¬ONSET¬BETWEEN¬THE¬TWINS¬AND UNRELATED¬2!¬PATIENTS¬ON¬THE¬RATE¬OF¬JOINT¬DESTRUCTION ¬THE¬3HARP¬SCORES¬OF¬%!#¬PATIENTS ¬AND¬ ¬YEARS¬WERE¬COMPARED ¬SHOWING¬NO¬SIGNIl¬CANT¬DIFFERENCE¬DURING¬¬YEARS¬FOL LOW UP 4HE¬PATIENTS¬INCLUDED¬IN¬THIS¬STUDY¬WERE¬DIAGNOSED¬WITH¬2!¬IN¬THE¬@¬YEARS¬OR¬BEGIN NING¬OF¬THE¬@¬YEARS¬7E¬DID¬NOT¬PROVIDE¬DETAILED¬DESCRIPTIONS¬OF¬TREATMENT¬HISTORY¬OF¬ ALL¬PATIENTS¬AND¬CANNOT¬EXCLUDE¬DIFFERENCES¬IN¬TREATMENT¬.EVERTHELESS ¬IN¬THE¬MENTIONED¬ TIME¬ ERAS¬ THERAPY¬ WITH¬ $-!2$S¬ WAS¬ STARTED¬ IN¬ A¬ RELATIVELY¬ LATE¬ STAGE¬ AND¬ MEDICATIONS OF¬CHOICE¬WERE¬AMONG¬OTHERS¬ANTIMALARIALS ¬OF¬WHICH¬IS¬KNOWN¬THAT¬THEIR¬ABILITY¬TO¬HALT DISEASE¬PROGRESSION¬IS¬LIMITED¬4HEREFORE ¬WE¬SUSPECT¬THAT¬CONSIDERING¬THE¬RELATIVELY¬MILD¬ MEDICATIONS¬USED¬IN¬THE¬@¬AND¬BEGIN¬@ ¬THE¬NATURAL¬DISEASE¬COURSE¬OF¬THE¬PATIENTS¬IS ONLY¬LIMITED¬AFFECTED
# HA P TER¬ 2%&%2%.#%3
¬ ¬ "EGOVICH¬ !" ¬ #ARLTON¬ 6% ¬ (ONIGBERG¬ ,! ¬ 3CHRODI¬ 3* ¬ #HOKKALIGAM¬ !0 ¬ !LEXANDER¬ (# ¬ ET¬ AL¬ !¬ MISSENSE¬ 3INGLE .UCLEOTIDE¬ 0OLYMORPHISM¬ IN¬ A¬ GENE¬ ENCODING¬ A¬ PROTEIN¬ TYRO SINE¬PHOSPHATASE¬040. ¬IS¬ASSOCIATED¬WITH¬2HEUMATOID¬!RTHRITIS¬!M¬*¬(UM¬'ENET¬
¬ ¬ VAN¬DER¬(ELM VAN¬-IL¬!( ¬7ESOLY¬*: ¬(UIZINGA¬47¬5NDERSTANDING¬THE¬GENETIC¬CONTRIBU TION¬TO¬RHEUMATOID¬ARTHRITIS¬#URR¬/PIN¬2HEUMATOL¬
¬ ¬ -AC'REGOR¬!* ¬3NIEDER¬( ¬2IGBY¬!3 ¬+OSKENVUO¬- ¬+APRIO¬* ¬!HO¬+ ¬ET¬AL¬#HARACTERISING¬ THE¬ QUANTITATIVE¬ GENETIC¬ CONTRIBUTION¬ TO¬ RHEUMATOID¬ ARTHRITIS¬ USING¬ DATA¬ FROM¬ TWINS¬ !RTHRITIS¬2HEUM¬
¬ ¬ VAN¬ !KEN¬ * ¬ VAN¬ "ILSEN¬ *( ¬ !LLAART¬ #& ¬ (UIZINGA¬ 47 ¬ "REEDVELD¬ &#¬ 4HE¬ ,EIDEN¬ %ARLY !RTHRITIS¬#LINIC¬#LIN¬%XP¬2HEUMATOL¬¬3UPPL¬ 3
¬ ¬ 6AN¬DER¬(EIJDE¬$-¬0LAIN¬8 RAYS¬IN¬RHEUMATOID¬ARTHRITIS¬OVERVIEW¬OF¬SCORING¬METHODS ¬ THEIR¬RELIABILITY¬AND¬APPLICABILITY¬"AILLIERES¬#LIN¬2HEUMATOL¬
